BioSpace News Archive

LumiraDx Limited received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450.

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the results of its special meeting of shareholders held earlier.

AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2023.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the Company will report financial results for the third quarter 2023 and corporate updates, before market open on Thursday, November 9, 2023.

BiomX Inc. announced that the Company will present data from Part 1 of its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa pulmonary infections in people with cystic fibrosis at the 37th Annual North American Cystic Fibrosis Conference, which is being held November 2-4, 2023, in Phoenix, Arizona.

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2023, and provided an update on recent corporate activities.

Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese medical device player in transcatheter structural heart device and neurovascular device, presented its GeminiOne® TEER technology, along with the early clinical experiences of the device at the 35th Transcatheter Cardiovascular Therapeutics (TCT) conference.

Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive results of two, 6-week, Phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and children with attention-deficit/hyperactivity disorder (ADHD).

Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”) today announced that it has been selected to present a poster from a study of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) in a tauopathy model of Alzheimer’s disease at the Society for Neuroscience’s Neuroscience 2023 meeting.

Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp., announced that it has completed the acquisition of Urotronic, Inc., a private medical device company that developed Optilume® drug-coated balloon technology used in interventional urology to treat urethral strictures and benign prostatic hyperplasia or enlarged prostate conditions.